Wen Wan to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Wen Wan has written about Diabetes Mellitus, Type 2.
Connection Strength
1.012
-
Costs and Health Care Utilization Analysis of Medical Group Visits for Adults With Type 2 Diabetes in Community Health Centers. Med Care. 2023 12 01; 61(12):866-871.
Score: 0.473
-
New Frontiers in Diabetes Care: Quality Improvement Study of a Population Health Team in Rural Critical Access Hospitals. J Gen Intern Med. 2023 03; 38(Suppl 1):56-64.
Score: 0.113
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.110
-
Factors related to recruitment and retention of patients into diabetes group visits in Federally Qualified Health Centers. J Eval Clin Pract. 2023 02; 29(1):146-157.
Score: 0.109
-
Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med. 2022 02; 37(2):439-448.
Score: 0.104
-
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
Score: 0.102